Welcome to our dedicated page for Danaher Corporation news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher Corporation stock.
Danaher Corporation (NYSE: DHR) is a global life sciences and diagnostics innovator whose news flow is closely followed by investors, healthcare professionals and industry observers. The company regularly issues press releases on its financial performance, capital allocation decisions and participation in major healthcare conferences, providing insight into how its life sciences and diagnostics businesses are performing and evolving.
On this page, readers can find news about Danaher’s quarterly and annual results, including updates on revenue trends, non‑GAAP core revenue growth and adjusted earnings, as described in its earnings releases and related Form 8‑K filings. The company frequently hosts earnings conference calls and webcasts, and it posts accompanying slide presentations, non‑GAAP reconciliations and notes on historical and anticipated financial performance in its investors materials.
Danaher also announces regular quarterly cash dividends on its common stock and discloses share repurchase authorizations, giving shareholders visibility into its capital allocation approach. In addition, news items cover leadership and governance developments, such as planned transitions in senior executive roles and changes in board composition, as documented in the company’s communications and SEC reports.
Beyond financial and corporate updates, Danaher’s news includes product and research announcements from its operating companies. For example, Beckman Coulter Diagnostics, a Danaher company, has reported the launch of a fully automated Brain‑derived Tau research use only immunoassay test and the development of an Aβ‑42 research use only immunoassay test to support neurodegenerative disease research. These stories illustrate how Danaher’s diagnostics businesses contribute to advanced clinical and research capabilities.
By reviewing the DHR news feed, users can monitor earnings announcements, dividend declarations, conference presentations, governance updates and scientific developments across Danaher’s life sciences and diagnostics platform. This page can be a useful resource for tracking how the company communicates its strategy, performance and innovation activities over time.
Beckman Coulter Diagnostics has received FDA 510(k) clearance for its new DxC 500i Clinical Analyzer, an integrated clinical chemistry and immunoassay system. The analyzer features:
- Throughput capacity of 800 clinical chemistry tests and 100 immunoassay tests per hour
- FlexMode operations for test prioritization
- Dynamic sample handler for automated repeats and re-runs
- Intuitive interface with proactive task indicators
The system is designed to support networked laboratory operational models, particularly relevant as approximately 45% of U.S. clinical laboratories (over 11,000) are part of Integrated Delivery Networks (IDNs). The analyzer has been available in CE mark countries since July 2024 and builds upon the previously released DxC 500 AU Chemistry Analyzer technology.
Danaher (NYSE: DHR) has announced that its President and CEO, Rainer M. Blair, will deliver a presentation at the upcoming TD Cowen Healthcare Conference in Boston, Massachusetts. The presentation is scheduled for Wednesday, March 5, 2025, at 10:30 a.m. ET.
The event will feature a simultaneous webcast accessible to interested parties through the 'Investors' section of Danaher's website under 'Events & Presentations' at www.danaher.com.
Danaher (NYSE: DHR) has appointed Charles Lamanna to its Board of Directors and the Board's Science & Technology Committee. Lamanna currently serves as Corporate Vice President, Business & Industry Copilot at Microsoft, where he leads product innovation in AI-powered business applications, low-code platforms, and autonomous agents.
Lamanna oversees design, product development, and engineering of Microsoft's key technologies, including Power Platform, Dynamics 365, and Copilot Studio. He previously founded MetricsHub, a public cloud management solution acquired by Microsoft in 2013. The Notre Dame computer science graduate brings significant AI and technology expertise to Danaher's board as the company aims to leverage artificial intelligence to improve human health and deliver long-term stakeholder value.
Danaher (NYSE: DHR) has announced an increase in its regular quarterly cash dividend. The Board of Directors approved a dividend of $0.32 per share of common stock, representing an 18.5% increase from the previous payment of $0.27. The dividend will be payable on April 25, 2025 to shareholders of record as of March 28, 2025.
TriLink BioTechnologies, a Maravai LifeSciences (NASDAQ: MRVI) company, has entered into a non-exclusive License and Supply Agreement with Aldevron for CleanCap® mRNA capping technology. The agreement allows Aldevron to use TriLink's patented CleanCap® analogs in mRNA development and manufacturing services through Phase III programs.
The agreement covers CleanCap® M6, CleanCap® AG 3'OMe, CleanCap® AG, and CleanCap® AU cap analogs. The CleanCap® technology delivers optimal 5'Cap structures with over 95% efficiency, improving mRNA yield and process time compared to traditional methods. The technology has been used in over 350 preclinical and clinical programs and is featured in most approved COVID-19 mRNA and saRNA vaccines.
Notably, the recently introduced CleanCap® M6 (May 2023) has demonstrated increased mRNA expression by more than 30% compared to enzymatic capping methods.
Danaher (NYSE: DHR) reported its Q4 and full-year 2024 results, showing mixed performance. In Q4 2024, revenues increased 2.0% year-over-year to $6.5 billion, with non-GAAP core revenue up 1.0%. Q4 net earnings reached $1.1 billion, or $1.49 per diluted share, with non-GAAP adjusted EPS of $2.14.
For full-year 2024, the company reported flat revenues at $23.9 billion, while non-GAAP core revenue decreased 1.5%. Net earnings were $3.9 billion, or $5.29 per diluted share, with non-GAAP adjusted EPS of $7.48. Operating cash flow was strong at $6.7 billion, with free cash flow of $5.3 billion.
Looking ahead to 2025, Danaher expects Q1 core revenue to decline low-single digits year-over-year, but projects full-year core revenue growth of approximately 3%.
Aldevron has launched Alchemy™, a revolutionary cell-free DNA technology for research grade applications. This innovative technology cuts linear DNA manufacturing time by over 50 percent while producing cleaner, safer DNA templates for mRNA synthesis.
The technology utilizes rolling circle amplification for DNA template production, eliminating the need for cells in DNA amplification. Key benefits include faster turnaround times, lower endotoxin levels, reduced host cell-derived impurities, and high-quality control specifications. The research grade version is currently available to support development and preclinical programs, with a cGMP offering planned for 2025 to support clinical applications.
Beckman Coulter Diagnostics has launched new Research Use Only (RUO) blood-based biomarker immunoassays for neurodegenerative disease research. The assays are designed to assess four key biomarkers: p-Tau217, GFAP, NfL, and APOE ε4, which are important in neurodegenerative diseases research and clinical trials.
The assays are available on the DxI 9000 Immunoassay Analyzer, featuring Lumi-Phos PRO substrate for high-sensitivity testing. GFAP, NfL, and APOE ε4 assays are also available on the Access 2 Immunoassay Analyzer. The APOE ε4 immunoassay offers over 99% concordance with PCR genotyping in just 20 minutes.
These automated, high-throughput platforms aim to improve workflow, precision, and reliability of biomarker testing for neurodegenerative diseases, potentially enabling broader multi-center research collaborations.
Danaher (NYSE: DHR) has announced that CEO Rainer M. Blair will discuss the company's Q4 2024 performance at the J.P. Morgan Healthcare Conference. The company expects Q4 2024 revenues to show a low-single digit percent increase year-over-year. The estimated non-GAAP core revenue for Q4 2024 is projected to be flat year-over-year, surpassing previous guidance which had anticipated a low-single digit percent decline. The company will hold its Q4 and full year 2024 earnings conference call on January 29, 2025.
Danaher (NYSE: DHR) has announced an investment partnership with Innovaccer Inc., a healthcare AI company, through its subsidiaries Danaher Diagnostics and Danaher Ventures. The partnership aims to enhance patient outcomes through digital and diagnostic solutions.
Innovaccer has developed software solutions that create unified patient records to identify care gaps and at-risk patients. The collaboration seeks to accelerate precision diagnostics adoption among clinicians and population health teams, supporting value-based care initiatives.
The partnership aligns with Danaher's mission to advance precision medicine through AI-enabled diagnostics, focusing on providing healthcare providers with data and analytics for faster clinical insights at the point of need.